Risk factors for the development of local recurrence in extremity soft-tissue sarcoma. Issue 1 (2nd January 2022)

• Record Type: Journal Article
• Authors: Tirotta, Fabio; Sayyed, Raza; Jones, Robin L; Hayes, Andrew J
• Is Part Of: Expert review of anticancer therapy. Volume 22:Issue 1(2022)
• Page Start: 83
• Page End: 95
• Publication Date: 2022-01-02
• Subjects: Extremity soft tissue sarcoma -- isolated limb perfusion -- local recurrence -- radiotherapy -- prognosis -- surgical oncology; Cancer -- Treatment -- Periodicals; 616.99406
• DOI: 10.1080/14737140.2022.2011723
• Languages: English
• ISSNs: 1473-7140

Abstract

ABSTRACT: Introduction: Local recurrence (LR) is one of the main pitfalls in surgery for extremities soft tissue sarcoma (eSTS). Achieving clear histopathological margins is the most important factor to reduce the risk of LR, but the ability to do so depends on not only surgical technique but also the interplay between tumor biology, anatomical location and surgical approach. The balance between postoperative morbidity and oncological benefits in reducing the risk of LR needs to be considered. Areas covered: This review will cover which etiological factors for the development of eSTS lead to an increased risk of LR and discuss histological subtypes that have a high risk of LR and which surgical and neoadjuvant therapeutic strategies can minimize the risk of LR. Expert opinion: The traditional view that surgical radicality always results in low rates of LR, while marginality alone always leads to high rates of relapse, is outdated. In the modern era of surgical oncology, limb salvage and high-level function after resectional surgery are the key surgical goals. The best results are achieved by combining effective neoadjuvant treatments with planned bespoke oncological operations that consider the biological and anatomical factors of each individual sarcoma.